Biocon Biologics and Viatris launch Abevmy in Canada EP News Bureau May 24, 2022 Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…
CCI approves Serum Institute Life Sciences-Biocon Biologics deal Press Trust of India May 19, 2022 Once the deal is complete, Serum Institute Life Sciences will have about 15 per cent stake in Biocon Biologics, according to the…
Biocon Q4FY22 revenue at Rs 2,476 crores, up 21 per cent IANS May 2, 2022 FY22 revenue at Rs 8,397 crores, up 14 per cent; core EBITDA up 18 per cent at Rs 2,669 crores; PBT (before Exceptional Item) at…
MoH, Malaysia, awards three-year contract to Biocon Biologics’s Insugen EP News Bureau Apr 26, 2022 Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices…
Biocon Biologics’ partner receives positive EU CHMP opinion for biosimilar human insulin for IV… EP News Bureau Apr 1, 2022 Celerity Pharma uses Biocon Biologics’ insulin drug substance to develop the product
Kiran Mazumdar-Shaw Elected as Fellow of Royal Society of Edinburgh EP News Bureau Mar 23, 2022 Shaw is among the 80 luminaries to be appointed to the RSE’s Fellowship this year
Biocon Biologics to acquire Viatris’ biosimilars assets for up to $3.335 billion EP News Bureau Feb 28, 2022 Viatris to provide commercial and other transition services for an expected period of two years to ensure continuity of customer…
Biocon’s consolidated Q3FY22 revenue grows by 18 per cent YoY to Rs 2,223 crores EP News Bureau Jan 22, 2022 Biosimilars up by 28 per cent at Rs 981 crores; research services up by 10 per cent at Rs 641 crores and generics up by seven per…
Viatris wins US court decisions on Sanofi appeals for Lantus device patents EP News Bureau Dec 30, 2021 Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Biocon Biologics initiates clinical study for Itolizumab in Lupus Nephritis EP News Bureau Dec 24, 2021 Equalise is a phase-Ib open-label, proof-of-concept clinical study currently studying Lupus Nephritis patients in the Part B…